Through this cooperation, DSM and PBC Biomed aim to strengthen their respective abilities to help medical device companies develop products that address the growing trends in medicine, from treating an aging population to caring for a more active one. The partners will initially focus on developing Biomimetic Innovations' proof-of-concept for regenerative bone adhesives which promise shorter operation times, lower infection rates, and better healing outcomes for patients.
Marc Hendriks, Senior Director Strategy and Business Development for DSM Biomedical, said: "We look forward to partnering with PBC Biomed and contributing DSM's biomaterials leadership and expertise towards the further development of bone adhesives and many others. Bone adhesives have the potential to transform orthopedics and vastly improve patient outcomes; in full support of our Vision of solving the world's healthcare needs through sustainable science."
Paul Burke, Managing Partner for PBC Biomed, said: "PBC Biomed is celebrating our 10th year of partnering with companies large and small to deliver science-based innovations in the medical device, biologic and pharmaceutical sectors. This agreement with Royal DSM brings us closer to our joint goal of accelerating medical innovation and enhancing patient wellness in the orthopaedic space."
DSM has more than 30 years' experience serving the medical device industry with world-class medical technologies and materials, and PBC Biomed has an impressive track record of science-based innovation in partnership with small, medium and global medical companies. Through the partnership, the companies aim to leverage their complementary technologies and capabilities to serve customers in the medical device industry with an integrated solution offering comprising materials design, product development, manufacturing process development, and manufacturing services.